Living affected individual (proband) where the individual +/- family history meets ONE of the criteria.
The proband has:
1. Rhabdomyosarcoma (≤ 5 years),
2. Rhabdomyosarcoma of embryonal anaplastic subtype (any age)
3. Adrenocortical cancer (any age),
4. Choroid plexus cancer (any age),
5. Breast cancer (≤ 30 years),
6. HER2 positive breast cancer (≤ 35 years),
7. Hypodiploid acute lymphoblastic leukaemia (<18 years) 8. SHH medulloblastoma (<18 years) 9. Jaw osteosarcoma (<18 years) 10. ≥2 LFS-related cancers (both occurring ≤ 46 years; two breast cancers not eligible), 11. ≥1 LFS-related cancer with ≥1 first / second degree relative with ≥1 LFS-related cancer (one case ≤ 46 years, the other case ≤ 56 years; two breast cancers not eligible), 12. Cancer with ≥2 first / second degree relatives with cancer; across the family there is: i. 1 individual with sarcoma ≤ 45 years, AND ii. 1 individual with any cancer ≤ 45 years, AND iii. 1 individual with either a sarcoma OR any cancer occurring ≤ 45 years 13. Proband with personal history of 2 or more POT1-associated cancers (cutaneous melanoma, chronic lymphocytic leukaemia, angiosarcoma, glioma but excluding two cases of cutaneous melanoma) OR Proband with POT1 associated cancer and ≥1 FDR/SDR affected with a POT1 associated cancer (excluding two cases of cutaneous melanoma) Deceased affected individual (proband) where all the following are met; (i) the individual +/- family history meets one of the above criteria, AND (ii) a previously stored constitutional blood/DNA or tissue sample (tumour or normal) is available, AND (iii) no living affected individual is available for genetic testing, AND (iv) after discussion at specialist cancer genetics MDT LFS-related cancers comprise: soft tissue sarcomas, osteosarcomas, adrenocortical carcinoma, central nervous system tumours and breast cancers including malignant phylloides tumours NOTE: The proband's cancer and majority of reported cancers in the family should have been confirmed Genetic testing may occasionally be appropriate outside these criteria following discussion at a specialist MDT with a cancer geneticist present Referrals for testing will be triaged by the Genomic Laboratory; testing should be targeted at those where a genetic or genomic diagnosis will guide management for the proband or family.

Living affected individual (proband) where the individual +/- family history meets ONE of the criteria.
The proband has:
1. Rhabdomyosarcoma (≤ 5 years),
2. Rhabdomyosarcoma of embryonal anaplastic subtype (any age)
3. Adrenocortical cancer (any age),
4. Choroid plexus cancer (any age),
5. Breast cancer (≤ 30 years),
6. HER2 positive breast cancer (≤ 35 years),
7. Hypodiploid acute lymphoblastic leukaemia (<18 years) 8. SHH medulloblastoma (<18 years) 9. Jaw osteosarcoma (<18 years) 10. ≥2 LFS-related cancers (both occurring ≤ 46 years; two breast cancers not eligible), 11. ≥1 LFS-related cancer with ≥1 first / second degree relative with ≥1 LFS-related cancer (one case ≤ 46 years, the other case ≤ 56 years; two breast cancers not eligible), 12. Cancer with ≥2 first / second degree relatives with cancer; across the family there is: i. 1 individual with sarcoma ≤ 45 years, AND ii. 1 individual with any cancer ≤ 45 years, AND iii. 1 individual with either a sarcoma OR any cancer occurring ≤ 45 years 13. Proband with personal history of 2 or more POT1-associated cancers (cutaneous melanoma, chronic lymphocytic leukaemia, angiosarcoma, glioma but excluding two cases of cutaneous melanoma) OR Proband with POT1 associated cancer and ≥1 FDR/SDR affected with a POT1 associated cancer (excluding two cases of cutaneous melanoma) Deceased affected individual (proband) where all the following are met; (i) the individual +/- family history meets one of the above criteria, AND (ii) a previously stored constitutional blood/DNA or tissue sample (tumour or normal) is available, AND (iii) no living affected individual is available for genetic testing, AND (iv) after discussion at specialist cancer genetics MDT LFS-related cancers comprise: soft tissue sarcomas, osteosarcomas, adrenocortical carcinoma, central nervous system tumours and breast cancers including malignant phylloides tumours NOTE: The proband's cancer and majority of reported cancers in the family should have been confirmed Genetic testing may occasionally be appropriate outside these criteria following discussion at a specialist MDT with a cancer geneticist present Referrals for testing will be triaged by the Genomic Laboratory; testing should be targeted at those where a genetic or genomic diagnosis will guide management for the proband or family.